NASDAQ: TRDA
Entrada Therapeutics Inc Stock Ownership - Who owns Entrada Therapeutics?

Insider buying vs selling

Have Entrada Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Mpm Bioventures 2018 LP10% Owner2026-09-0928,837$7.13
$205.61kSell
Mpm Bioventures 2014 LP10% Owner2026-09-0928,837$7.13
$205.61kSell
Mpm Bioventures 2014 LP10% Owner2026-09-08192,500$7.41
$1.43MSell
Mpm Bioventures 2018 LP10% Owner2026-09-08192,500$7.41
$1.43MSell
Mpm Bioventures 2014 LP10% Owner2026-09-0438,500$7.11
$273.74kSell
Mpm Bioventures 2018 LP10% Owner2026-09-0438,500$7.11
$273.74kSell
Mpm Bioventures 2018 LP10% Owner2026-09-0332,263$7.17
$231.33kSell
Mpm Bioventures 2014 LP10% Owner2026-09-0332,263$7.17
$231.33kSell
Mpm Bioventures 2018 LP10% Owner2026-09-0225,131$7.19
$180.69kSell
Kory James WentworthCFO2026-09-021,733$7.14
$12.38kSell

1 of 8

TRDA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRDA insiders and whales buy or sell their stock.

TRDA Shareholders

What type of owners hold Entrada Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Kush Parmar23.05%8,973,386$48.28MInsider
Mpm Bioventures 2018 LP21.23%8,266,177$44.47MInsider
Mpm Bioventures 2014 LP21.23%8,266,177$44.47MInsider
5am Ventures V LP15.67%6,102,764$32.83MInsider
Baker Bros Advisors LP12.05%4,691,392$25.24MInsider
Todd Foley11.37%4,425,784$23.81MInsider
Roche Holding Ltd7.23%2,813,525$15.14MInsider
Redmile Group LLC5.02%1,954,420$10.51MInsider
Dipal Doshi1.33%517,290$2.78MInsider
Natarajan Sethuraman0.55%214,238$1.15MInsider

1 of 3

TRDA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRDA0.06%99.94%Net SellingNet Selling
WHWK0.08%79.52%Net Buying
ANTX0.07%61.05%Net SellingNet Selling
ELDN0.06%37.81%Net SellingNet Selling
ALEC0.08%43.37%Net SellingNet Selling

Entrada Therapeutics Stock Ownership FAQ

Who owns Entrada Therapeutics?

Entrada Therapeutics (NASDAQ: TRDA) is owned by 0.07% institutional shareholders, 120.00% Entrada Therapeutics insiders, and 0.00% retail investors. Kush Parmar is the largest individual Entrada Therapeutics shareholder, owning 8.97M shares representing 23.05% of the company. Kush Parmar's Entrada Therapeutics shares are currently valued at $48.28M.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.